News
-
-
PRESS RELEASE
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
CROSSJECT secures $11.3 million BARDA funding for ZEPIZURE® development towards FDA authorization. Advances include validation batches and facility audit completion -
-
-
-
-
-
-
-